The board of directors at Southern California's Valeant Pharmaceuticals International approved a $100 million repurchase of its outstanding common stock as part of its 2007 stock repurchase program.
In a company press release, Valeant's chairperson and CEO J. Michael Pearson said, "The board's authorization of the additional $100 million to the share repurchase program underscores its continued confidence in our strategy and our commitment to enhancing shareholder value." The repurchase will bring the total authorized amount to $300 million. The board approved the first $200 million last June.
- See Valeant's release [1]
- get more [2] at MSN
Related Articles:
Valeant chops workforce in restructuring [3]
Valeant shares jump on epilepsy trial data [4]
Valeant sells development programs [5]
Valeant hep C drug fails pivotal trial, again [6]
Valeant to out-license programs in restructuring [7]
Links:
[1] http://www.fiercebiotech.com/press-releases/valeant-pharmaceuticals-announces-increase-share-repurchase-authorization
[2] http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=AP&date=20080617&id=8787438
[3] http://www.fiercebiotech.com/story/valeant-chops-workforce-in-restructuring/2008-05-02?utm_medium=rss&utm_source=rss&cmp-id=OTC-RSS-FB0
[4] http://www.fiercebiotech.com/story/valeant-shares-jump-on-epilepsy-trial-data/2008-02-13
[5] http://www.fiercebiotech.com/story/spotlight-valeant-sells-development-programs/2006-12-22
[6] http://www.fiercebiotech.com/story/valeant-hep-c-drug-fails-pivotal-trial-again/2006-09-12
[7] http://www.fiercebiotech.com/story/valeant-to-out-license-programs-in-restructuring/2006-04-04